SUMMARY Carcinoembryonic antigen (CEA) and elastase 1 in the serum were determined by enzyme immunoassay and radioimmunoassay, respectively, in 224 healthy subjects, 49 patients with pancreatitis, 53 patients with pancreatic carcinoma and 129 patients with cancer in other organs. The CEA concentrations in the serum were significantly higher in patients with pancreatic carcinoma than in those with pancreatitis, but this concentration was not a satisfactory indicator of pancreatic carcinoma localised to allow irradication by resection as it was raised in only 47% of the patients. High CEA concentrations were also slightly, but not significantly, more frequent in patients with cancer of the pancreatic body or tail, and unresectable cancer or cancer of more than 6.0 cm in longest diameter than in those with cancer of the pancreatic head, resectable cancer or cancer of less than 6-0 cm diameter. Serum elastase 1 was raised in only 42% of the patients with pancreatic carcinoma and could not be used to distinguish patients with pancreatic carcinoma from those with pancreatitis. In contrast with CEA, however, its concentration was abnormally high significantly more frequently in patients with cancer of less than-6.0 cm in longest diameter than in those with larger tumours. It was also raised slightly, but not significantly, more frequently in those with cancer of the pancreatic head and in patients with resectable cancer than in those with unresectable cancer. A combination of these two tests raised the diagnostic rate of pancreatic carcinoma to 77% without a remarkable decrease in the specificity for pancreatic carcinoma. In particular, it raised the diagnostic rates of cases of cancer of the pancreatic head, resectable cancer and cancers of less than 3.0 cm and 3.0-6.0 cm in longest diameter. Therefore, a combination of measurements of CEA and elastase 1 in the serum is very useful for early detection of pancreatic carcinoma.
with pancreatitis, 53 patients with pancreatic carcinoma and 129 patients with cancer in other organs. The CEA concentrations in the serum were significantly higher in patients with pancreatic carcinoma than in those with pancreatitis, but this concentration was not a satisfactory indicator of pancreatic carcinoma localised to allow irradication by resection as it was raised in only 47% of the patients. High CEA concentrations were also slightly, but not significantly, more frequent in patients with cancer of the pancreatic body or tail, and unresectable cancer or cancer of more than 6.0 cm in longest diameter than in those with cancer of the pancreatic head, resectable cancer or cancer of less than 6-0 cm diameter. Serum elastase 1 was raised in only 42% of the patients with pancreatic carcinoma and could not be used to distinguish patients with pancreatic carcinoma from those with pancreatitis. In contrast with CEA, however, its concentration was abnormally high significantly more frequently in patients with cancer of less than-6.0 cm in longest diameter than in those with larger tumours. It was also raised slightly, but not significantly, more frequently in those with cancer of the pancreatic head and in patients with resectable cancer than in those with unresectable cancer. A combination of these two tests raised the diagnostic rate of pancreatic carcinoma to 77% without a remarkable decrease in the specificity for pancreatic carcinoma. In particular, it raised the diagnostic rates of cases of cancer of the pancreatic head, resectable cancer and cancers of less than 3.0 cm and 3.0-6.0 cm in longest diameter. Therefore, a combination of measurements of CEA and elastase 1 in the serum is very useful for early detection of pancreatic carcinoma. Data on serum CEA, elastase 1 and a combination of these two markers in healthy subjects, patients with benign and malignant pancreatic diseases and patients with cancer in other organs are summarised in Table 1 . The CEA concentration in the serum was significantly higher in patients with benign and malignant pancreatic diseases and in patients with cancer in other organs than in healthy subjects. The serum CEA concentration was significantly higher in patients with pancreatic carcinoma than in those with pancreatitis, while the difference in mean values between patients with pancreatic carcinoma and with cancer in other organs was not statistically significant. The serum elastase 1 concentrations were also significantly higher in patients with benign and malignant pancreatic diseases and in patients with cancer in other organs than in healthy subjects. Although the elastase 1 concentration in the serum was significantly higher in patients with pancreatic carcinoma than in those with cancer in other organs, the difference in mean values between patients with pancreatic carcinoma and with pancreatitis was not statistically significant. Of the sera obtained from 224 healthy subjects, 217 (97%) had CEA concentrations of less than 5.0 ng/ml and all had elastase 1 concentrations of less than 500 ng/dl. Therefore, in this study, abnormally high CEA and elastase 1 concentrations in the serum were defined as those of more than 5.0 ng/ml and 500 ng/dl, respectively. As shown in Table 2 guided percutaneous aspiration biopsy of the pancreas20 for early diagnosis of pancreatic carcinoma. In the present study, we obtained correct diagnoses in 47% of the cases by measurement of serum CEA only, in 42% of the cases by measurement of elastase 1, and in 77% of the cases by a combination of these two tests and this combination of tests for pancreatic carcinoma did not decrease the specificity remarkably. In particular, the combination of assays raised the diagnostic rate for cases of cancer of the pancreatic head, resectable cancer and cancer of less than 3.0 cm and 3(0-60 cm in longest diameter to 77%, 71%, 80%, and 70%, respectively. Therefore, a combination of measurements of CEA and elastase 1 in the serum seems very useful for early detection of pancreatic carcinoma. In practice, patients with high CEA and/or elastase 1 concentrations were examined more extensively by ultrasonographic and computed tomographic investigations or endoscopic retrograde pancreatography, thus reducing the rate of overlooking cases of pancreatic carcinoma. In this series, 21 (40%) of 53 cases of pancreatic cancer were still sufficiently localised to allow irradication by resection. 
